Avita initiates Recell trial for vitiligo repigmentation

Avita Therapeutics has enrolled the first patient in a pivotal study of its Recell system for the treatment of stable vitiligo, the company announced in a press release.

The multicenter study will evaluate the safety and efficacy of the Recell system, which is designed to repigment skin in patients who have vitiligo that has been stable for at least 1 year.

Participating clinicians will use a small amount of the patient’s own healthy skin to prepare a suspension of spray-on skin cells using the Recell system, which will then be applied to the lesions, the release said.

“The initiation of the vitiligo clinical study is a milestone in advancing Avita Therapeutics’ pipeline to leverage the utility and full potential of our innovative Recell technology platform to address unmet medical needs in dermatological applications,” Mike Perry, PhD, CEO of Avita Therapeutics, said in the release. “Globally, there have been several published case series and pilot randomized clinical trials reporting positive results with the use of Recell for treating patients with stable vitiligo and repigmenting depigmented skin lesions.”